Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA-208a (miR-208a) is a small, non-coding RNA molecule (~22 nucleotides) that plays a crucial role in the regulation of gene expression in the heart. Encoded within an intron of the α-cardiac muscle myosin heavy chain gene (*MYH6*), miR-208a is specifically expressed in cardiac tissue and is essential for normal cardiac growth, function, and electrical conduction. It acts predominantly as a post-transcriptional regulator, targeting mRNAs for degradation or translation inhibition. MiR-208a is a key regulator of pathological cardiac hypertrophy and arrhythmogenesis; its overexpression induces hypertrophy and arrhythmia, whereas its inhibition attenuates pathological remodeling after cardiac stress. It also modulates systemic energy metabolism and is being investigated as both a therapeutic target and a circulating biomarker for cardiac diseases[1][3][5].
Inhibition of miR-208a (using antagomirs/antisense oligonucleotides) to reduce cardiac hypertrophy and maladaptive remodeling[3]. Modulation of downstream gene expression by altering mRNA stability and translation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA-208a (miR-208a).